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More than 30 % of patients with colorectal 
cancer developed liver metastases. 
Radical surgical resection of liver 
metastases remains the only chance of 
cure with more than 50% 5-year survival. 
Unfortunately, most of the patients are 
presented with unresectable metastases 
because of their size, number, location or 
inadequate liver remnant after resection. 
In unresectable disease, many ablative 
approaches can be used. The most 
frequent is radiofrequency ablation(RFA). 
However, RFA is less effective in the 
treatment of metastases in the vicinity of 
major hepatic vessels due to heat sink 
effect. 
From 2009 to 2018 35 patients with 
colorectal liver metastases were 
treated with electrochemoterapy at 
our department. In our first published 
analyses, 29 metastases in 16 patients 
were treated with electrochemoterapy 
during open surgery by US-guided 
insertion of long needle electrodes (with 
variable or fixed geometry) into and 
around the tumor. Up to three metastases 
not exceeding 3 cm in the diameter were 
treated with electrochemoterapy. Patients 
were divided into three groups. In the 
first two groups were patients with two-
stage liver surgery. In the first operation, 
some of the metastases were treated 
by electrochemoterapy and removed 
during the second operations. In the 
third group patients with unresectable 
metachronous metastases were treated 
with electrochemoterapy as the only 
treatment option. 
There was no perioperative mortality. 
Three patients required reoperation after 
electrochemoterapy; two because of 
colon perforation and one because of 
obstruction of small bowel because of 
adhesions. None of these complications 
were related to electrochemoterapy. 
During or after electrochemoterapy no 
major heart rhythm changes or myocardial 
ischemia were found. 
Radiological complete response was 
observed in 85% of treated metastases 
and partial in 15% after the first 
radiological evaluation. At the second 
evaluation, at a median of 147 days after 
electrochemoterapy, 71% of metastases 
were still in complete response. Response 
to electrochemoterapy was the same in 
metastases located close to major hepatic 
vessels and metastases away from the 
vessels. On pathological analysis, non 
treated metastases had a significantly 
higher percentage of residual viable tumor 
compared to electrochemoterapy treated. 
We found regressive changes in the whole 
electrochemoterapy-treated area of the 
liver with disruption of vessels less than 
5 mm in diameter and preservation of the 
larger vessels and biliary ducts. 
Electrochemoterapy of liver metastases 
is feasible, efficient and safe treatment 
modality, especially for the metastases in 
the vicinity of major hepatic vessels.
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Abstract: Electrochemotherapy provides non-thermal ablation of cutaneous as well as deep 
seated tumors. Based on positive results of the treatment of colorectal liver metastases, we 
conducted a prospective pilot study on hepatocellular carcinomas with the aim of testing 
the feasibility, safety and effectiveness of electrochemotherapy. Electrochemotherapy with 
bleomycin was performed on 17 hepatocellular carcinomas in 10 patients using a previously 
established protocol. The procedure was performed during open surgery and the patients were 
followed for median 30 months. Electrochemotherapy was feasible for all 17 lesions, and no 
treatment-related adverse events or major post-operative complications were observed. The 
median size of the treated lesions was 24 mm (range 8-41 mm), located either centrally, i.e., near 
the major hepatic vessels, or peripherally. At last radiological follow-up the complete response 
rate was 90% per patient (9/10) and 94% per treated lesion (16/17). Electrochemotherapy of 
hepatocellular carcinoma proved to be a feasible and safe treatment in all 10 patients included 
in this study. To evaluate the effectiveness of this method, longer observation period is needed; 
however, the results at medium observation time of 30 months after treatment are encouraging, 
in 16 out of 17 lesions complete response was obtained. Electrochemotherapy is predominantly 
applicable in patients with impaired liver function due to liver cirrhosis and/or with lesions where 
a high-risk operation is needed to achieve curative intent, given the intra/perioperative risk for 
high morbidity and mortality.
INTRODUCTION
Hepatocellular carcinoma (HCC), together 
with intrahepatic cholangiocarcinoma, 
represents more than 98.5% of all primary 
liver tumors, and its incidence is rising 
worldwide. HCC is the third most common 
cause of cancer-related deaths in the 
world and is responsible for between 
650,000 and one million deaths globally 
per year (1-3).
The optimal treatment options for 
patients with HCC are curative surgical 
resection, liver transplantation and, in rare 
cases, radio-frequency ablation (RFA). 
Other methods, such as local ablative 
techniques (percutaneous ethanol (PEI) or 
acetic acid injection (PAI) in tumor, RFA, 
microwave ablation (MWA), transarterial 
chemoembolization (TACE), targeted 
therapy, chemo- and radiotherapy 
and others are used only as palliative 
treatment and in some cases as bridging 
therapy (TACE, RFA) for possible curative 
liver transplantation. Most patients with 
HCC are complex, with only 20% having 
straight forward treatment scenarios. 
Therefore, the majority of patients (more 
than 60%) receive some combination of 
therapies, depending on the stage of the 
disease (4-10).
Despite intensive surveillance programs, 
considerable recent therapeutic advances, 
and the use of potentially radical 
treatments, prognosis and life expectancy 
remain low in patients with HCC (11). 
Electroporation-based treatments, 
including irreversible electroporation (IRE) 
and electrochemotherapy, are new local 
treatment approaches that are gaining 
importance. Electrochemotherapy already 
has an established place among other 
local treatments for the treatment of 
cutaneous tumors (12), but the translation 
of electrochemotherapy into deep-seeded 
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tumors is lagging behind (13).
However, the first encouraging results for 
the treatment of colorectal liver metastases 
have already been published (14,15). 
Based on the encouraging clinical results, 
we conducted a prospective pilot clinical 
study to establish the feasibility, safety, 
and effectiveness of electrochemotherapy 
in the treatment of HCC. In the study, 
patients not amenable to other therapeutic 
ablative techniques were included. 
Furthermore, electrochemotherapy was 
also employed to treat tumors located 
in the vicinity of the major blood vessels 
where other ablative techniques, such 
as RFA or MWA, would not have been 
efficient due to the heat sink effect.
PATIENTS AND METHODS
Study design
The study was designed as a prospective, 
pilot study. Patients were presented 
at the multidisciplinary team meetings 
consisting of a surgeon, radiologist 
and gastro-oncologist. Before inclusion 
into the trial, all patients signed written 
informed consent. The primary endpoint 
of the study was to assess the feasibility 
and safety of electrochemotherapy in the 
treatment of HCC. The secondary aim was 
to determine the efficacy of ECT, based on 
a radiological evaluation of treated lesions, 
as measured by modified Choi criteria 
(17). Electrochemotherapy was performed 
according to the Standard Operating 
Procedures for treatment of cutaneous 
tumors and the associated modifications 
for the treatment of liver tumors and 
reporting of data according the published 
recommendations (15,18,19).
Patients
In this trial, 10 patients with 17 lesions were 
enrolled from February 2014 to November 
2016, based on the inclusion and 
exclusion criteria (Table 1). The diagnosis 
was confirmed either histologically (in 4 
patients) (20), or by typical radiological 
appearance according to the EASL-
EORTC Clinical Practice Guidelines for 
Management of hepatocellular carcinoma 
(5). Patients were divided into three groups 
according to the indications and previous 
treatments.
The first group represented patients 
in whom the local ablative technique 
was unsuccessful (TACE/RFA) and 
electrochemotherapy was offered as 
an additional treatment. In this group, 
3 patients with 6 lesions were treated. 
Two of these patients underwent TACE, 
which was unsuccessful (progress of the 
treated lesion at the follow up), and further 
treatment with TACE was not indicated. 
According to the Barcelona Clinic Liver 
Cancer (BCLC) algorithm (21), treatment 
for advanced or terminal stage disease 
should be offered. The third patient in this 
group had previously been treated with 
RFA, which was unsuccessful, and other 
ablative techniques were not indicated.
The second group included patients for 
whom transplantation, radical surgery 
or other local ablative techniques 
were not indicated due to patients' 
performance status, the location of 
the lesions, or contraindications to 
the ablative techniques. However, 
electrochemotherapy was performed with 
curative intent. In this group, 6 patients 
with 9 lesions were treated.
The third group included a patient for 
whom electrochemotherapy was offered 
as “bridging” to transplantation option. 
In this patient, 2 lesions were treated. 
During the first procedure in 2009, right 
hemihepatectomy with resection of middle 
and right hepatic veins in un-cirrhotic liver 
was performed due to HCC. In 2015, the 
patient developed 2 new HCC lesions 
located in proximity to the left hepatic 
vein, so electrochemotherapy was offered 
to the patient as a “bridging” to liver 
transplantation.
Lesions were defined as “central” or 
“peripheral” based on their relation to the 
major blood vessels. The term “central” 
was used for the lesions in the close vicinity 
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of the major blood vessels including 
the main hepatic or portal veins and the 
main hepatic arterial branches. The term 
“peripheral” was used for lesions not 
adjacent to the major blood vessels where 
RFA or other ablative techniques were 
not indicated by interventional radiologist 
blinded to the study (22,23). 
Treatment procedure
All 10 patients enrolled in the study were 
treated during open surgery. Median 
laparotomy, extended to the right 
subcostal incision, was performed in 8/10 
patients. In 2 patients, only upper median 
laparotomy was used. The electrodes 
used for electric pulse delivery were either 
single long (20 cm) needle electrodes 
(variable geometry) with 3 or 4 cm active 
part or 7-needle electrodes fixed on the 
holder in hexagonal geometry and 3 cm 
active part (24,25). The choice of electrode 
use was dependent on the location of the 
lesion. Electrodes with variable geometry 
i.e., long needle electrodes were used for 
deep seated tumors located more than 
3 cm below the surface of the liver. The 
hexagonal electrodes were used for more 
superficial tumors that had their deepest 
margins less than 3 cm from the liver 
surface (24,25). Specifically, the treatment 
of lesions in segment 8 included the use of 
both types of the electrodes, where for the 
use of hexagonal electrodes mobilization 
of the liver was required. The intraoperative 
ultrasound was used to identify lesions 
and aid the positioning of the electrodes 
into and around the tumor. The long needle 
electrodes were positioned according to 
the pretreatment plan prepared for each 
patient and specific tumor individually 
using previously developed procedures 
(26,27). Plans were developed based on 
computed tomography and/or magnetic 
resonance scans taken less than 30 
days prior to treatment. Target lesions 
(up to 41 mm in the largest diameter) 
were segmented. A gradient-based 
optimization algorithm was used to 
optimize voltage between each electrode 
pair to maximize tumor coverage above 
the reversible electroporation threshold 
(400 V/cm) and minimize the volume 
of healthy liver parenchyma above the 
irreversible electroporation threshold 
(700 V/cm). The intravenous bolus of 
bleomycin was given to the patient after 
the intra-operative ultrasound confirmed 
the correct electrode placement. Trains 
of eight electric pulses (electrodes with 
variable geometry) or 24 (fixed geometry) 
electric pulses (each pulse 100 ms long) 
were delivered to each pair of electrodes 
consecutively. Electric pulses were 
delivered by electric pulse generator 
during an interval of 8-28 min after the 
intravenous injection of bleomycin 15,000 
IU/m2 in bolus, as being determined to be 
the optimal pharmacological peak for the 
bleomycin in the tumors (16).
Efficacy assessment based on radiology
Lesions treated in the study were assessed 
before electrochemotherapy by contrast-
enhanced computed tomography (CECT) 
or with magnetic resonance imaging 
(CEMRI) using a distinct hepatocyte 
contrast (gadoliniumethoxybenzyl-
diethylenetriaminepentaacetic acid-Gd-
EOB-DTPA). The follow-up was performed 
by CECT in all the patients but one in whom 
the CEMRI was performed at the 3- months 
follow-up. Images were evaluated by two 
radiologists, one of whom was blinded to 
the trial. Modified Choi criteria were used 
to assess the treatment response (17). 
Evaluations of both radiologists were in 
complete consensus.
RESULTS
Feasibility, safety, and response to 
treatment evaluation were evaluated for 
all 10 patients and 17 lesions.
Feasibility
Electrochemotherapy was feasible in all 10 
patients enrolled in the study, according 
to the inclusion and exclusion criteria 
(Table 1). Three females and 7 males were 
included, with a median age 69.5 years 
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(range: 57-78 years). Three patients had 
undergone previous treatment with TACE 
and/or RFA, and one had undergone 
liver resection. Six patients had received 
electrochemotherapy as a primary 
treatment. The previously operated patient 
had electrochemotherapy as a bridging 
procedure for liver transplantation.
Patients were treated according to the 
Standard Operating Procedures for 
cutaneous tumors, modified for the liver 
tumors during open surgery (16,24). 
The median size of the treated lesions 
was 24 mm with a range of 8-41 mm. 
Electrochemotherapy was also feasible in 
patients with centrally located lesions in 
the vicinity of major hepatic vessels (8/17 
lesions).
Safety
Adverse reactions related to electro-
chemotherapy did not occur, despite the 
American Society of Anesthesiologists 
(ASA) score of 3 (8/10 patients) and ASA 
score of 2 (2/10 patients). No intraoperative 
or postoperative complications during 
the first 24 h occurred. The exceptions 
were the two patients with the ascites 
production after the procedure due to 
transient liver failure. Ascites was resolved 
by conservative measures. Nevertheless, 
patients were classified as Clavien-Dindo 
3a and 3b because in both additional 
diagnostic/intervention was necessary: in 
one patient the ERCP was performed due 
to choledocholithiasis; the second patient 
had elevation of cholestatic enzymes and 
the endoscopic ultrasound was performed 
to clarify the origin of elevated enzymes. 
The impaired liver function was a result of 
liver cirrhosis before the operation and was 
not related to the electrochemotherapy.
All 10 patients were discharged from the 
hospital after a median hospitalization 
of 5.5 days (range: 2-20 days) and were 
followed on an outpatient basis. ECG 
signals were recorded during and 24 h 
after the electrochemotherapy. No onset of 
new or worsening of existing pathological 
morphological changes was recorded. 
There were no signs of myocardial 
ischemia, new-onset of atrial and/or 
ventricular extrasystoles, or increased 
frequency of abnormal heartbeats in 
Table 1 Inclusion and exclusion criteria for electrochemotherapy in HCC. 
Inclusion criteria
1. HCC confirmed by radiological imaging and/or histology. 
2. Age more than 18 years.
3. Life expectancy more than 3 months.
4. Performance status Karnofsky 70 or WHO (World Health Organization) < 2.
5. Signed informed consent.
6. Unanimous decision of the multidisciplinary liver tumor team before entering the trial 
(surgeon, gastro-oncologist and radiologist).
Exclusion criteria
1. Multiple primary tumors.
2. Extrahepatic disease.
3. Poor performance status.
4. Clinically significant ascites.
5. Exposure to cumulative bleomycin doses in excess of 400 mg.
6. Allergic reaction to bleomycin.
7. Impaired kidney function (Creatinine > 150 mmol/l).
8. Pregnancy, epilepsy, heart arrhythmias or patient having cardiac pace maker.
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relation to the electrochemotherapy 
procedure. Centrally located tumor 
lesions (8/17) near major hepatic vessels 
were successfully treated without adverse 
events.
Effectiveness
The first radiologic follow-up was 1 month 
after treatment (median 31 days; range 
from 23 to 45 days). All 17 lesions were 
evaluated and a complete response was 
found in 15/17 lesions (88%). Two lesions 
had a partial response according to the 
modified Choi criteria, due to the small 
field of enhancement, without changes in 
lesion size.
The second radiological follow-up was 3-6 
months after the treatment (median 194 
days; range from 100 to 218 days). All 17 
lesions were evaluated, and according to 
the modified Choi criteria, all of the lesions 
that had been initially evaluated after 1 
month, i.e., the 15/17 lesions, remained in 
complete response. Two lesions identified 
in the previous follow-up as partial 
responses (2/17, 12%) remained in the 
stage of partial response and the patients 
were considered being in stable disease.
The last radiological follow-up was 12-
37 months after the treatment (median 
30 months). One of the lesion that was 
previously evaluated as stable disease, 
was described as complete response after 
last radiological follow-up. The rest of the 
lesions remained unchanged, therefore a 
complete response was observed in 16/17 
lesions (94%).
DISCUSSION
Electrochemotherapy has, after successful 
translation into treatment of cutaneous 
tumors, progressed into translation of 
deep seated tumors. This study confirmed 
the feasibility, safety and effectiveness 
of electrochemotherapy in the treatment 
of HCC. No treatment or postoperative 
adverse events were recorded, including 
in patients with lesions located near 
the major hepatic vessels. The overall 
response was high, 94% (16/17) of the 
treated lesions and 90% (9/10) of patients 
had complete responses.
The feasibility and safety of 
electrochemotherapy was already 
demonstrated in a previous study on the 
treatment of colorectal liver metastases. 
The response rate of that study was 85% 
complete responses on 29 metastases 
in 16 patients which is comparable to 
the 94% complete response rate in this 
prospective pilot study on HCC (15). The 
technology that has proven to be feasible 
and safe in the previous study was also 
confirmed in this study and another 
recently published study (14), in cases 
where other ablative techniques are not 
indicated.
In this study, not only patients with 
previously unsuccessfully treated tumors, 
but also patients for whom standard 
treatment with curative intent could not 
be offered were included. In one patient, 
this method was used as a bridging to 
liver transplantation. Two patients had 
post-operative complications in the form 
of transient liver function failure with 
consequent ascites production. Based on 
poor performance status of the recruited 
patients in whom other treatments 
were not feasible, electrochemotherapy 
provides effective treatment of lesions 
in such patients. Therefore, it could be 
considered as a technique with curative 
intent, which, however, needs to be 
confirmed in a phase II study in a larger 
cohort of patients.
One of the limitations of this approach 
is that larger tumors tend to have lower 
response rates. As indicated by several 
other studies, tumors larger than 3 cm 
in diameter seldom have complete 
responses (28,29). The method in our case 
was upgraded by the treatment plan that 
intended to predict the optimal electrode 
placement for effective electroporation 
of the tumors. This certainly aided 
better execution of the electroporation 
of lesions larger than 3 cm in diameter, 
but the step for effective verification of 
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the tumor coverage after electroporation 
is still missing. This can be executed 
either by US verification, as noted in IRE 
and also by electrochemotherapy, or by 
development of measuring tools for the 
current distribution in the tumors by MRI, 
which is still in progress (29-31).
This study, however, has some limitations. 
Based on the fact that it is a pilot study 
and on small cohort of patients, only ten, 
the conclusion about the effectiveness 
of electrochemotherapy is premature. 
Nevertheless, the preliminary data foster 
the continuation of this study in phase II 
one.
In conclusion, our experience 
demonstrate feasibility, safety and 
provides preliminary data on the high 
effectiveness of electrochemotherapy 
in HCC. Electrochemotherapy could be 
predominantly applicable in patients with 
impaired liver function due to liver cirrhosis 
and/or with lesions where a high-risk 
operation is needed to achieve curative 
intent.
REFERENCES
1. Forner A, Llovet JM, Bruix J. Hepatocellular 
carcinoma. Lancet 2012;379(9822):1245e55. 
2. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc 
W, Taylor-Robinson SD. Hepatocellular 
carcinoma: current trends in worldwide 
epidemiology, risk factors, diagnosis, and 
therapeutics. Expert Rev Gastroenterol 
Hepatol 2009;3(4): 353e67. 
3. Bosch FX, Ribes J, Cleries R, Díaz M. 
Epidemiology of hepatocellular carcinoma. 
Clin Liver Dis 2005;9:191e211. 
4. Llovet JM, Bustamante J, Castells A, Vilana 
R, Ayuso MC, Sala M, et al. Natural history 
of untreated nonsurgical hepatocellular 
carcinoma: rationale for the design and 
evaluation of therapeutic trials. Hepatology 
1999;29(1):62e7. 
5. European Association For The Study Of 
The Liver. EASLeEORTC clinical practice 
guidelines: management of hepatocellular 
carcinoma. J Hepatol 2012;56(4):908e43. 
6. Figueras J, Jaurrieta E, Valls C, Ramos R, 
Serrano T, Rafecas A, et al. Resection or 
transplantation for hepatocellular carcinoma 
in cirrhotic patients: outcomes based on 
indicated treatment strategy. J Am Coll Surg 
2000;190(5):580e7.
7. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan 
R, Wu V, et al. Liver transplantation for 
hepatocellular carcinoma: analysis of survival 
according to the intention-to-treat principle 
and dropout from the waiting list. Liver Transpl 
2002;8(10):873e83.
8. Bruix J, Sherman M. Management of 
hepatocellular carcinoma. Hepatology 
2005;42(5):1208e36. 
9. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. 
Systematic review of randomized trials 
for hepatocellular carcinoma treated with 
percutaneous ablation therapies. Hepatology 
2009;49(2):453e9.
10. Teratani T, Yoshida H, Shiina S, Obi S, Sato S, 
Tateishi R, et al. Radiofrequency ablation for 
hepatocellular carcinoma in so-called high-
risk locations. Hepatology 2006;43(5):1101e8. 
11. Cabibbo G, Craxì A. Hepatocellular cancer: 
optimal strategies for screening and 
surveillance. Dig Dis 2009;27(2):142e7.
12. Bertino G, Sersa G, De Terlizzi F, Occhini 
A, Plaschke CC, Groselj A, et al. European 
research on electrochemotherapy in head 
and neck cancer (EURECA) project: results 
of the treatment of skin cancer. Eur J Cancer 
2016;63:41e52.
13. Scheffer HJ, Nielsen K, De Jong MC, Tilborg 
AJM, Vieveen JM, Bouwman RA, et al. 
Irreversible electroporation for nonthermal 
tumor ablation in the clinical setting: a 
systematic review of safety and efficacy. J 
Vasc Interv Radiol 2014: 997e1011.
14. Coletti L, Battaglia V, De Simone P, Turturici L, 
Bartolozzi C, Filipponi F. Safety and feasibility 
of electrochemotherapy in patients with 
unresectable colorectal liver metastases: a 
pilot study. Int J Surg 2017;44:26e32.
15. Edhemovic I, Brecelj E, Gasljevic G, Music 
MMarolt, Gorjup V, Mali B, et al. Intraoperative 
electrochemotherapy of colorectal liver 
metastases. J Surg Oncol 2014;110(3):320e7. 
39
16. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, 
Billard V, et al. Standard operating procedures 
of the electrochemotherapy: instructions for 
the use of bleomycin or cisplatin administered 
either systemically or locally and electricpulses 
delivered by the CliniporatorTM by means 
of invasive or non-invasive electrodes. Eur J 
Cancer Suppl 2006:14e25. 
17. Weng Z, Ertle J, Zheng S, Lauenstein T, Mueller 
S, Bockisch A, et al. Choi criteria are superior 
in evaluating tumor response in patients 
treated with transarterial radioembolization for 
hepatocellular carcinoma. Oncol lett 2013;6: 
1707e12. 
18. Marty M, Sersa G, Garbay JR, Gehl J, Collins 
CG, Snoj M, et al. Electrochemotherapy 
e an easy, highly effective and safe 
treatment of cutaneous and subcutaneous 
metastases: results of ESOPE (European 
Standard Operating Procedures of 
Electrochemotherapy) study. Eur J Cancer 
Suppl 2006;4(11): 3e13. 
19. Campana LG, Clover AJP, Valpione S, Quaglino 
P, Gehl J, Kunte C, et al. Recommendations 
for improving the quality of reporting clinical 
electrochemotherapy studies based on 
qualitative systematic review. Radiol Oncol 
2016:1e13. 
20. McGahan JP, Bishop J, Webb J, Howell L, 
Torok N, Lamba R, et al. Role of FNA and core 
biopsy of primary and metastatic liver disease. 
Int J Hepatol 2013;2013:174103. 
21. Saraswat VA, Pandey G, Shetty S. Treatment 
algorithms for managing hepatocellular 
carcinoma. J Clin Exp Hepatol 2014;4(3):80e9. 
22. Komorizono Y, Oketani M, Sako K, Yamasaki 
N, Shibatou T, Maeda M, et al. Risk factors 
for local recurrence of small hepatocellular 
carcinoma tumors after a single session, single 
application of percutaneous radiofrequency 
ablation. Cancer 2003;97(5):1253e62.
23. Llovet J, Vilana R, Brú C, Bianchi L, Salmeron 
JM, Boix L, et al. Increased risk of tumor 
seeding after percutaneous radiofrequency 
ablation for single hepatocellular carcinoma. 
Hepatology 2001;33(5):1124e9.
24. Miklavcic D, Sersa G, Brecelj E, Gehl J, Soden 
D, Bianchi G, et al. Electrochemotherapy: 
technological advancements for efficient 
electroporationbased treatment of internal 
tumors. Med Biol Eng Comput 2012;50(12): 
1213e25. 
25. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, 
Pucihar G, Snoj M. Electrochemotherapy 
in treatment of tumours. Eur J Surg Oncol 
2008;34(2):232e40. 
26. Marcan M, Pavliha D, Kos B, Forjanic T, 
Miklavcic D. Web-based tool for visualization 
of electric field distribution in deep-
seated body structures and planning of 
electroporation-based treatments. Biomed 
Eng Online 2015;14(Suppl 3):S4. 
27. Zupanic A, Kos B, Miklavcic D. Treatment 
planning of electroporation-based medical 
interventions: electrochemotherapy, gene 
electrotransfer and irreversible electroporation. 
Phys Med Biol 2012;57(17):5425e40. 
28. Zeng J, Liu G, Li Z, Yang Y, Fang G, Li R, et 
al. The safety and efficacy of irreversible 
electroporation for large hepatocellular 
carcinoma. Technol Cancer Res Treat 
2017;16(1):120e4. 
29. Bhutiani N, Doughtie CA, Martin RCG. 
Ultrasound validation of mathematically 
modeled irreversible electroporation ablation 
areas. Surgery 2016; 159(4):1032e40.
30. Sersa I, Kranjc M, Miklavcic D. Current density 
imaging sequence for monitoring current 
distribution during delivery of electric pulses 
in irreversible electroporation. Biomed Eng 
Online 2015;14(Suppl 3):1e12.
31. Kranjc M, Kranjc S, Bajd F, Sersa G, Sersa 
I, Miklavcic D. Predicting irreversible 
electroporation-induced tissue damage 
by means of magnetic resonance 
electrical impedance tomography. Sci Rep 
2017;7(1):10323.
